美国 · SEC FORM 4
Harmony Biosciences Holdings, Inc.
HRMY · Nasdaq · CIK 0001802665 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
17 同一窗口内观察到的 Form 4 交易行
7 sales · 10 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2020-08-26 · Nielsen Jack.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 5,532,301
- 上期报告
- 4,628,716
- 日均成交量
- 1,108,114
- 回补天数
- 5.0
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2020-08-26 | Nielsen Jack | 买入 (P) | Common Stock | 3,922 | USD 34.30 | USD 134,525 | SEC 申报 ↗ |
| 2020-08-25 | Nielsen Jack | 买入 (P) | Common Stock | 823 | USD 34.20 | USD 28,147 | SEC 申报 ↗ |
| 2020-08-24 | Nielsen Jack | 买入 (P) | Common Stock | 3,057 | USD 34.30 | USD 104,855 | SEC 申报 ↗ |
| 2020-08-21 | Marshman Fund Trust II | 买入 (P) | Common Stock | 339,476 | USD 24.00 | USD 8,147,424 | SEC 申报 ↗ |
| 2020-08-21 | Novo Holdings A/S | 买入 (P) | COMMON STOCK | 132,503 | USD 24.00 | USD 3,180,072 | SEC 申报 ↗ |
| 2020-08-21 | Nielsen Jack | 买入 (P) | Common Stock | 32,164 | USD 26.31 | USD 846,191 | SEC 申报 ↗ |
| 2020-08-20 | Nielsen Jack | 买入 (P) | Common Stock | 2,736 | USD 35.00 | USD 95,760 | SEC 申报 ↗ |
Form 4 申报证据
43 transaction lines in the latest 365-day window; 310 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | Budur Kumar | 卖出 (S) | Common Stock | 35,852 | USD 43.05 | USD 1,543,429 | SEC 申报 ↗ |
| 2026-09-18 | Budur Kumar | 期权行权/转换 (M) | Common Stock | 35,852 | USD 30.39 | USD 1,089,611 | SEC 申报 ↗ |
| 2026-09-17 | Budur Kumar | 卖出 (S) | Common Stock | 800 | USD 43.00 | USD 34,400 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | Budur Kumar | 卖出 (S) | Common Stock | 35,852 | USD 43.05 | USD 1,543,429 | SEC 申报 ↗ |
| 2026-09-18 | Budur Kumar | 期权行权/转换 (M) | Common Stock | 35,852 | USD 30.39 | USD 1,089,611 | SEC 申报 ↗ |
| 2026-09-17 | Budur Kumar | 卖出 (S) | Common Stock | 800 | USD 43.00 | USD 34,400 | SEC 申报 ↗ |
| 2026-09-17 | Budur Kumar | 期权行权/转换 (M) | Common Stock | 800 | USD 30.48 | USD 24,384 | SEC 申报 ↗ |
| 2026-09-16 | Budur Kumar | 卖出 (S) | Common Stock | 1,800 | USD 43.01 | USD 77,418 | SEC 申报 ↗ |
| 2026-09-16 | Budur Kumar | 期权行权/转换 (M) | Common Stock | 1,800 | USD 30.48 | USD 54,864 | SEC 申报 ↗ |
| 2026-09-08 | Budur Kumar | 卖出 (S) | Common Stock | 28,454 | USD 42.95 | USD 1,222,232 | SEC 申报 ↗ |
| 2026-09-08 | Budur Kumar | 期权行权/转换 (M) | Common Stock | 22,954 | USD 30.49 | USD 699,942 | SEC 申报 ↗ |
| 2026-09-04 | Budur Kumar | 卖出 (S) | Common Stock | 5,500 | USD 41.98 | USD 230,890 | SEC 申报 ↗ |
| 2026-05-01 | Budur Kumar | 期权行权/转换 (M) | Common Stock | 18,750 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-01 | Budur Kumar | 代扣税 (F) | Common Stock | 8,882 | USD 31.83 | USD 282,714 | SEC 申报 ↗ |
| 2026-04-07 | Zaeske Adam H. | 期权行权/转换 (M) | Common Stock | 7,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-07 | Zaeske Adam H. | 代扣税 (F) | Common Stock | 3,173 | USD 27.62 | USD 87,638 | SEC 申报 ↗ |
| 2026-01-26 | Kapadia Sandip | 卖出 (S) | Common Stock | 3,746 | USD 37.15 | USD 139,164 | SEC 申报 ↗ |
| 2026-01-25 | Serafin Andrew | 期权行权/转换 (M) | Common Stock | 2,600 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-25 | Serafin Andrew | 代扣税 (F) | Common Stock | 1,126 | USD 36.82 | USD 41,459 | SEC 申报 ↗ |
| 2026-01-25 | Kapadia Sandip | 期权行权/转换 (M) | Common Stock | 4,725 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-25 | Kapadia Sandip | 代扣税 (F) | Common Stock | 2,553 | USD 36.82 | USD 94,001 | SEC 申报 ↗ |
| 2026-01-25 | Dayno Jeffrey M. | 期权行权/转换 (M) | Common Stock | 13,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-25 | Dayno Jeffrey M. | 代扣税 (F) | Common Stock | 5,654 | USD 36.82 | USD 208,180 | SEC 申报 ↗ |
| 2026-01-25 | Budur Kumar | 期权行权/转换 (M) | Common Stock | 2,662 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-25 | Budur Kumar | 代扣税 (F) | Common Stock | 1,372 | USD 36.82 | USD 50,517 | SEC 申报 ↗ |
| 2026-01-24 | Serafin Andrew | 期权行权/转换 (M) | Common Stock | 2,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-24 | Serafin Andrew | 代扣税 (F) | Common Stock | 1,116 | USD 36.82 | USD 41,091 | SEC 申报 ↗ |
| 2026-01-24 | Kapadia Sandip | 期权行权/转换 (M) | Common Stock | 3,813 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-24 | Kapadia Sandip | 代扣税 (F) | Common Stock | 2,239 | USD 36.82 | USD 82,440 | SEC 申报 ↗ |
| 2026-01-24 | Dayno Jeffrey M. | 期权行权/转换 (M) | Common Stock | 10,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-24 | Dayno Jeffrey M. | 代扣税 (F) | Common Stock | 4,785 | USD 36.82 | USD 176,184 | SEC 申报 ↗ |
| 2026-01-24 | Budur Kumar | 期权行权/转换 (M) | Common Stock | 2,188 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-24 | Budur Kumar | 代扣税 (F) | Common Stock | 1,153 | USD 36.82 | USD 42,453 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | HRMY |
| CIK | 0001802665 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 310 transaction lines from 2020-08-20 to 2026-09-18 8 P purchase lines · 186 S sale lines · 116 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.